• Soleno's drug misses key goal in Prader-Willi trial pharmatimes
    June 10, 2020
    Soleno Therapeutics has unveiled new data showing that its diazoxide choline controlled release (DCCR) tablets failed to reduce hyperphagia – or an abnormal desire for food – in patients with Prader-Willi syndrome.
PharmaSources Customer Service